{"id":"https://openalex.org/W2554518403","doi":"https://doi.org/10.1182/blood.v120.21.1341.1341","title":"Crenolanib Is A Highly Potent, Selective, FLT3 TKI with Activity Against D835 Mutations","display_name":"Crenolanib Is A Highly Potent, Selective, FLT3 TKI with Activity Against D835 Mutations","publication_year":2012,"publication_date":"2012-11-16","ids":{"openalex":"https://openalex.org/W2554518403","doi":"https://doi.org/10.1182/blood.v120.21.1341.1341","mag":"2554518403"},"language":"en","primary_location":{"id":"doi:10.1182/blood.v120.21.1341.1341","doi":"https://doi.org/10.1182/blood.v120.21.1341.1341","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood.v120.21.1341.1341","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5039615665","display_name":"Allison Galanis","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I145311948","display_name":"Johns Hopkins University","ror":"https://ror.org/00za53h95","country_code":"US","type":"education","lineage":["https://openalex.org/I145311948"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Allison Galanis","raw_affiliation_strings":["Oncology, Johns hopkins University, Baltimore, MD, USA,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Oncology, Johns hopkins University, Baltimore, MD, USA,","institution_ids":["https://openalex.org/I145311948"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5022563226","display_name":"Trivikram Rajkhowa","orcid":"https://orcid.org/0000-0002-5478-8580","observed_orcids":["https://orcid.org/0000-0002-5478-8580"]},"institutions":[{"id":"https://openalex.org/I145311948","display_name":"Johns Hopkins University","ror":"https://ror.org/00za53h95","country_code":"US","type":"education","lineage":["https://openalex.org/I145311948"]},{"id":"https://openalex.org/I2799853436","display_name":"Johns Hopkins Medicine","ror":"https://ror.org/037zgn354","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I2799853436"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Trivikram Rajkhowa","raw_affiliation_strings":["Oncology and Pediatrics, The Johns Hopkins University School of Medicine, Baltimore, MD, USA,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Oncology and Pediatrics, The Johns Hopkins University School of Medicine, Baltimore, MD, USA,","institution_ids":["https://openalex.org/I145311948","https://openalex.org/I2799853436"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5060236493","display_name":"Chaitanya Muralidhara","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210115489","display_name":"Arog Pharmaceuticals (United States)","ror":"https://ror.org/01rgp0j22","country_code":"US","type":"company","lineage":["https://openalex.org/I4210115489"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Chaitanya Muralidhara","raw_affiliation_strings":["Arog Pharmaceuticals, Dallas, TX,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Arog Pharmaceuticals, Dallas, TX,","institution_ids":["https://openalex.org/I4210115489"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5048425494","display_name":"Abhijit Ramachandran","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210115489","display_name":"Arog Pharmaceuticals (United States)","ror":"https://ror.org/01rgp0j22","country_code":"US","type":"company","lineage":["https://openalex.org/I4210115489"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Abhijit Ramachandran","raw_affiliation_strings":["AROG Pharmaceuticals LLC, Dallas, TX, USA,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"AROG Pharmaceuticals LLC, Dallas, TX, USA,","institution_ids":["https://openalex.org/I4210115489"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5089694123","display_name":"Mark J. Levis","orcid":"https://orcid.org/0000-0003-0473-6982","observed_orcids":["https://orcid.org/0000-0003-0473-6982","https://orcid.org/0000-0003-4219-6315"]},"institutions":[{"id":"https://openalex.org/I145311948","display_name":"Johns Hopkins University","ror":"https://ror.org/00za53h95","country_code":"US","type":"education","lineage":["https://openalex.org/I145311948"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Mark J. Levis","raw_affiliation_strings":["Johns Hopkins University School of Medicine, Baltimore, MD, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Johns Hopkins University School of Medicine, Baltimore, MD, USA","institution_ids":["https://openalex.org/I145311948"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":3,"corresponding_author_ids":["https://openalex.org/A5022563226","https://openalex.org/A5048425494","https://openalex.org/A5060236493"],"corresponding_institution_ids":["https://openalex.org/I145311948","https://openalex.org/I2799853436","https://openalex.org/I4210115489"],"apc_list":{"value":5500,"currency":"USD","value_usd":5500},"apc_paid":null,"fwci":0.4089,"has_fulltext":false,"cited_by_count":5,"citation_normalized_percentile":{"value":0.69325669,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":88,"max":95},"biblio":{"volume":"120","issue":"21","first_page":"1341","last_page":"1341"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10309","display_name":"Acute Myeloid Leukemia Research","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10309","display_name":"Acute Myeloid Leukemia Research","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11215","display_name":"Chronic Myeloid Leukemia Treatments","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11559","display_name":"Retinoids in leukemia and cellular processes","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/crenolanib","display_name":"crenolanib","score":0.921999990940094},{"id":"https://openalex.org/keywords/flt3-inhibitors","display_name":"FLT3 inhibitors","score":0.9369999766349792},{"id":"https://openalex.org/keywords/flt3-itd-mutation","display_name":"FLT3-ITD","score":0.9269999861717224},{"id":"https://openalex.org/keywords/acute-myeloid-leukemia","display_name":"acute myeloid leukemia","score":0.9890000224113464},{"id":"https://openalex.org/keywords/quizartinib","display_name":"quizartinib","score":0.8119999766349792},{"id":"https://openalex.org/keywords/myelosuppression","display_name":"myelosuppression","score":0.9819999933242798},{"id":"https://openalex.org/keywords/drug-resistance","display_name":"drug resistance","score":0.3869999945163727},{"id":"https://openalex.org/keywords/pharmacokinetics","display_name":"pharmacokinetics","score":0.5170000195503235},{"id":"https://openalex.org/keywords/erythroid-colony-formation","display_name":"erythroid colony formation","score":0.6150000095367432},{"id":"https://openalex.org/keywords/glioma","display_name":"glioma","score":0.5040000081062317},{"id":"https://openalex.org/keywords/gastrointestinal-stromal-tumor","display_name":"gastrointestinal stromal tumor","score":0.9769999980926514},{"id":"https://openalex.org/keywords/pdgfr","display_name":"PDGFR","score":0.5260000228881836}],"concepts":[{"id":"https://openalex.org/C42362537","wikidata":"https://www.wikidata.org/wiki/Q87099740","display_name":"Tyrosine kinase","level":3,"score":0.5968042612075806},{"id":"https://openalex.org/C2778729363","wikidata":"https://www.wikidata.org/wiki/Q11688946","display_name":"Myeloid leukemia","level":2,"score":0.5869418382644653},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.5300248265266418},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.48192858695983887},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.4666471481323242},{"id":"https://openalex.org/C2910954276","wikidata":"https://www.wikidata.org/wiki/Q14912399","display_name":"Fms-Like Tyrosine Kinase 3","level":4,"score":0.43545836210250854},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.39355960488319397},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.33268633484840393},{"id":"https://openalex.org/C501734568","wikidata":"https://www.wikidata.org/wiki/Q42918","display_name":"Mutation","level":3,"score":0.31291863322257996},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.29824522137641907},{"id":"https://openalex.org/C170493617","wikidata":"https://www.wikidata.org/wiki/Q208467","display_name":"Receptor","level":2,"score":0.1666298508644104},{"id":"https://openalex.org/C104317684","wikidata":"https://www.wikidata.org/wiki/Q7187","display_name":"Gene","level":2,"score":0.11722862720489502},{"id":"https://openalex.org/C54355233","wikidata":"https://www.wikidata.org/wiki/Q7162","display_name":"Genetics","level":1,"score":0.1115913987159729}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1182/blood.v120.21.1341.1341","doi":"https://doi.org/10.1182/blood.v120.21.1341.1341","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood.v120.21.1341.1341","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"score":0.9391000270843506,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W1971716764","https://openalex.org/W2069727776","https://openalex.org/W1984712646","https://openalex.org/W2603465065","https://openalex.org/W2740214316","https://openalex.org/W2026119169","https://openalex.org/W2942338535","https://openalex.org/W918891332","https://openalex.org/W2739994418","https://openalex.org/W2551344052"],"abstract_inverted_index":{"Abstract":[0,1],"1341":[2],"Approximately":[3],"23%":[4,252],"of":[5,16,48,51,88,95,120,155,175,187,200,223,232,240,246,337,346,361,367,373,388,409,433],"acute":[6],"myeloid":[7],"leukemia":[8],"(AML)":[9],"patients":[10,91,305,326],"have":[11,195,270],"internal":[12],"tandem":[13],"duplications":[14],"(ITD)":[15],"the":[17,46,61,118,124,201,271,314,464],"type":[18,203],"III":[19,204],"receptor":[20,205],"tyrosine":[21,55,206],"kinase":[22,56],"FLT3.":[23,219],"FLT3/ITD":[24,81],"mutations":[25,94,108,144],"correlate":[26],"with":[27,104,115,198,228,243,257,353,370,385,406,425],"poor":[28],"survival":[29],"rates":[30],"in":[31,79,127,172,184,279,285,293,318,365,412],"AML":[32,82],"patients.":[33,83,156,297],"This":[34],"has":[35,70,139,145],"made":[36],"FLT3":[37,54,64,105,135,162,317,343,374],"a":[38,49,72,77,134,153,159,290,371,380,422,431,441],"promising":[39],"target":[40],"for":[41,152,181,277,316,329,396,457],"treating":[42,458],"AML,":[43],"leading":[44],"to":[45,67,102,148,218,249,308],"development":[47],"series":[50,366],"small":[52],"molecule":[53],"inhibitors":[57],"(TKIs).":[58],"Quizartinib":[59],"is":[60,130,158,165,210,451,466],"most":[62],"potent":[63,168],"TKI":[65,136,163,456],"developed":[66,92],"date,":[68],"and":[69,253,259,295,327,355,391,393,436],"achieved":[71,352],"high":[73],"response":[74],"rate":[75],"as":[76,167,169,216,275,289],"monotherapy":[78],"relapsed/refractory":[80],"However,":[84],"during":[85],"clinical":[86,185,280],"trials":[87,186,288],"quizartinib,":[89,188,390,435],"multiple":[90],"point":[93,143],"aspartate":[96],"835":[97],"(D835)":[98],"which":[99,137,164,193],"conferred":[100],"resistance":[101],"treatment":[103],"TKIs.":[106],"FLT3/D835":[107,142,459],"can":[109,349],"also":[110,138],"occur":[111],"at":[112],"disease":[113],"presentation":[114],"or":[116],"without":[117],"presence":[119],"ITD":[121],"mutations,":[122],"though":[123],"prognostic":[125],"significance":[126,222],"these":[128,301,325,338],"cases":[129],"less":[131,212],"well-defined.":[132],"Therefore,":[133],"activity":[140,332,360,402],"against":[141,214,403],"significant":[146,272,442],"potential":[147,454],"be":[149,351],"clinically":[150],"beneficial":[151],"number":[154],"Crenolanib":[157,209,282],"next":[160],"generation":[161],"nearly":[166],"quizartinib":[170,258,278,426],"(IC50":[171],"human":[173],"plasma":[174,330],"35":[176],"nM":[177,180,245,387,411],"versus":[178],"18":[179],"quizartinib).":[182],"Furthermore,":[183],"some":[189],"subjects":[190],"experienced":[191],"myelosuppression,":[192],"may":[194,268],"been":[196],"associated":[197],"inhibition":[199],"related":[202],"kinase,":[207],"c-Kit.":[208],"33-fold":[211],"active":[213],"c-Kit":[215],"compared":[217,248],"The":[220,238,335,359],"functional":[221],"this":[224,347,404],"finding":[225],"was":[226,251,283,363,383],"tested":[227,364],"colony":[229],"formation":[230],"assays":[231,339],"normal":[233],"donor":[234],"bone":[235],"marrow":[236],"(n=3).":[237],"abundance":[239],"erythroid":[241],"colonies":[242],"200":[244],"drug":[247,310,348],"control":[250],"75%":[254],"when":[255],"treated":[256,384,424],"crenolanib,":[260,437],"respectively.":[261],"These":[262,445],"data":[263,299,446],"suggest":[264,340,448],"that":[265,304,341,449],"clinically,":[266],"crenolanib":[267,362,392,399,439,450],"not":[269],"myelosuppressive":[273],"effects":[274],"observed":[276],"trials.":[281],"studied":[284],"phase":[286],"II":[287],"PDGFR":[291],"inhibitor":[292],"glioma":[294],"GIST":[296],"Pharmacokinetic":[298],"from":[300,324,421],"trails":[302],"show":[303],"are":[306],"able":[307],"achieve":[309],"levels":[311],"well":[312],"above":[313],"IC90":[315],"plasma.":[319],"Plasma":[320],"samples":[321,369],"were":[322,419],"obtained":[323,420],"utilized":[328],"inhibitory":[331,344],"(PIA)":[333],"assays.":[334],"results":[336],"adequate":[342],"concentrations":[345],"easily":[350],"safe":[354],"tolerable":[356],"dosing":[357],"schedules.":[358],"primary":[368],"variety":[372],"mutations.":[375],"One":[376],"patient":[377,423],"sample":[378],"containing":[379],"D835V":[381],"mutation":[382],"20":[386],"sorafenib,":[389,434],"Western":[394],"blotted":[395],"pFLT3.":[397],"Only":[398],"showed":[400],"any":[401],"sample,":[405],"an":[407,452],"IC50":[408],"2":[410],"culture":[413],"medium.":[414],"In":[415,430],"another":[416],"case,":[417],"blasts":[418],"who":[427],"then":[428],"relapsed.":[429],"comparison":[432],"only":[438],"had":[440],"cytotoxic":[443],"effect.":[444],"strongly":[447],"important":[453],"new":[455],"mutated":[460],"AML.":[461],"Accrual":[462],"into":[463],"trial":[465],"ongoing":[467],"(NCT01522469).":[468],"Disclosures:":[469],"Muralidhara:":[470],"Arog":[471],"Pharmaceuticals":[472,476],"LLC:":[473,477],"Employment.":[474,478],"Ramachandran:Arog":[475],"Levis:Ambit":[479],"Biosciences:":[480],"Consultancy.":[481]},"counts_by_year":[{"year":2024,"cited_by_count":1},{"year":2020,"cited_by_count":1},{"year":2016,"cited_by_count":1},{"year":2013,"cited_by_count":2}],"updated_date":"2026-09-26T08:19:03.415552","created_date":"2016-11-30T00:00:00"}